Market capitalization | $1.78b |
Enterprise Value | $1.01b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.43 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-501.88m |
Free Cash Flow (TTM) Free Cash Flow | $-363.61m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
19 Analysts have issued a Denali Therapeutics Inc. forecast:
19 Analysts have issued a Denali Therapeutics Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -7.80 -7.80 |
102%
102%
|
|
EBITDA | -494 -494 |
172%
172%
|
EBIT (Operating Income) EBIT | -502 -502 |
155%
155%
|
Net Profit | -423 -423 |
191%
191%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Ryan Watts |
Employees | 422 |
Founded | 2013 |
Website | www.denalitherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.